A significant advance in Philips’ unique portfolio of systems, smart devices, software and services in image-guided therapy, the scalable IntraSight platform is based on Philips’ common software and hardware architecture.

Further providing seamless integration in the interventional lab, Philips SyncVision, available on IntraSight [4], advances patient care by mapping both the pressure profile and IVUS measurements of the whole vessel onto the angiogram. With iFR pullback and co-registration and IVUS co-registration [1], physicians can identify the precise locations causing ischemia, plan stent length and placement with a virtual stent, and predict physiologic improvement.


iFR is an innovative pressure-derived index proprietary to Philips, allowing a simplified hyperemia-free physiological assessment of coronary blockages. It continues to be adopted into clinical practice, with mounting evidence that this innovative technology contributes to reducing costs, improving outcomes [2, 3, 4] and enhancing the patient experience. IntraSight, SyncVision and iFR are part of Philips’ unique portfolio in image-guided therapy, delivering sophisticated, procedure-oriented solutions to healthcare providers.


About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

Back to HCB News

Cardiology Homepage